Humacyte Stock Performance
| HUMA Stock | USD 0.89 0.07 7.29% |
The company retains a Market Volatility (i.e., Beta) of 2.36, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Humacyte will likely underperform. At this point, Humacyte has a negative expected return of -0.58%. Please make sure to check out Humacyte's treynor ratio and the relationship between the skewness and day typical price , to decide if Humacyte performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Humacyte has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's primary indicators remain somewhat strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Brokerages Set Humacyte, Inc. Price Target at 8.29 | 12/09/2025 |
2 | Wall Street Zen Upgrades Humacyte to Hold - MarketBeat | 12/12/2025 |
3 | Humacyte Announces Credit Facility of Up to 77.5 Million with Avenue Capital | 12/16/2025 |
4 | 4 Altcoins Face Critical Events Before Christmas UNI, HYPE, ASTER, and HUMA | 12/22/2025 |
5 | Humacyte Announces Planned Marketing Authorization Application for Symvess in Israel | 01/05/2026 |
6 | Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications | 01/08/2026 |
7 | Acquisition by Dale Sander of 20000 shares of Humacyte at 1.53 subject to Rule 16b-3 | 01/09/2026 |
8 | While institutions invested in Humacyte, Inc. benefited from last weeks 10 percent gain, retail investors stood to gain the most | 01/12/2026 |
9 | Humacyte Given New 10.00 Price Target at Benchmark - MarketBeat | 01/21/2026 |
10 | Humacyte, Inc. Receives 8.14 Average Target Price from Analysts | 01/26/2026 |
11 | Humacyte, Inc. Exceeds Market Returns Some Facts to Consider - Yahoo Finance | 02/02/2026 |
| Begin Period Cash Flow | 80.8 M | |
| Total Cashflows From Investing Activities | -1.6 M |
Humacyte Relative Risk vs. Return Landscape
If you would invest 135.00 in Humacyte on November 8, 2025 and sell it today you would lose (46.00) from holding Humacyte or give up 34.07% of portfolio value over 90 days. Humacyte is currently does not generate positive expected returns and assumes 4.7637% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Humacyte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Humacyte Target Price Odds to finish over Current Price
The tendency of Humacyte Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.89 | 90 days | 0.89 | roughly 97.0 |
Based on a normal probability distribution, the odds of Humacyte to move above the current price in 90 days from now is roughly 97.0 (This Humacyte probability density function shows the probability of Humacyte Stock to fall within a particular range of prices over 90 days) .
Humacyte Price Density |
| Price |
Predictive Modules for Humacyte
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Humacyte. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Humacyte Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Humacyte is not an exception. The market had few large corrections towards the Humacyte's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Humacyte, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Humacyte within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.93 | |
β | Beta against Dow Jones | 2.36 | |
σ | Overall volatility | 0.15 | |
Ir | Information ratio | -0.18 |
Humacyte Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Humacyte for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Humacyte can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Humacyte generated a negative expected return over the last 90 days | |
| Humacyte has some characteristics of a very speculative penny stock | |
| Humacyte has high historical volatility and very poor performance | |
| Humacyte has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (148.7 M) with loss before overhead, payroll, taxes, and interest of (73.8 M). | |
| Humacyte currently holds about 189.04 M in cash with (98.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Humacyte, Inc. Exceeds Market Returns Some Facts to Consider - Yahoo Finance |
Humacyte Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Humacyte Stock often depends not only on the future outlook of the current and potential Humacyte's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Humacyte's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 118.5 M | |
| Cash And Short Term Investments | 44.9 M |
Humacyte Fundamentals Growth
Humacyte Stock prices reflect investors' perceptions of the future prospects and financial health of Humacyte, and Humacyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Humacyte Stock performance.
| Return On Equity | -2.5 | ||||
| Return On Asset | -0.63 | ||||
| Operating Margin | (32.39) % | ||||
| Current Valuation | 207.19 M | ||||
| Shares Outstanding | 193 M | ||||
| Price To Earning | 18.04 X | ||||
| Price To Book | 70.17 X | ||||
| Price To Sales | 117.71 X | ||||
| Gross Profit | (73.8 M) | ||||
| EBITDA | (132.23 M) | ||||
| Net Income | (148.7 M) | ||||
| Cash And Equivalents | 189.04 M | ||||
| Cash Per Share | 1.84 X | ||||
| Total Debt | 16.54 M | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 17.46 X | ||||
| Book Value Per Share | (0.03) X | ||||
| Cash Flow From Operations | (98.12 M) | ||||
| Earnings Per Share | (0.26) X | ||||
| Market Capitalization | 184.93 M | ||||
| Total Asset | 137.87 M | ||||
| Retained Earnings | (686.01 M) | ||||
| Working Capital | 27.91 M | ||||
About Humacyte Performance
By analyzing Humacyte's fundamental ratios, stakeholders can gain valuable insights into Humacyte's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Humacyte has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Humacyte has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.24) | (1.18) | |
| Return On Capital Employed | (1.12) | (1.17) | |
| Return On Assets | (1.24) | (1.18) | |
| Return On Equity | 3.25 | 3.41 |
Things to note about Humacyte performance evaluation
Checking the ongoing alerts about Humacyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Humacyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Humacyte generated a negative expected return over the last 90 days | |
| Humacyte has some characteristics of a very speculative penny stock | |
| Humacyte has high historical volatility and very poor performance | |
| Humacyte has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (148.7 M) with loss before overhead, payroll, taxes, and interest of (73.8 M). | |
| Humacyte currently holds about 189.04 M in cash with (98.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Humacyte, Inc. Exceeds Market Returns Some Facts to Consider - Yahoo Finance |
- Analyzing Humacyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Humacyte's stock is overvalued or undervalued compared to its peers.
- Examining Humacyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Humacyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Humacyte's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Humacyte's stock. These opinions can provide insight into Humacyte's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Humacyte Stock analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |